NCT05687448View on ClinicalTrials.gov

DIrect Oral Anticoagulation and Bioprothesis Aortic Valve

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,500

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

March 31, 2029

Conditions
Aortic Valve Disease
Interventions
DRUG

Apixaban 5 MG Oral Tablet

Patients treated with apixaban 5 mg twice daily (BID)

DRUG

Aspirin 75 to 100mg once a day

Patients treated with Aspirin 75 to 100mg once a day

Trial Locations (1)

75010

Service de Cardiologie Hôpital Lariboisière, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER